DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

Q: How long will it take to read this news story?

The story "DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth" has 344 words across 10 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth" was covered 16 hours ago by GlobeNewswire, a news publisher based in China.

Q: How trustworthy is 'GlobeNewswire' news outlet?

GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news. The outlet is headquartered in China and publishes an average of 80 news stories per day. It's most recent story was published 8 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26459266</li><li>URL: https://beamstart.com/news/dss-inc-announces-sale-of-17405766579362</li></ul>

GlobeNewswire 16h ago

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth - GlobeNewswire

Quick Summary:

"Impact BioMedical is well-positioned to leverage Celios’® innovative air purification technology, and we believe this transition will maximize the platform’s potential while allowing DSS to continue to focus into areas with stronger long-term synergies.” This transaction strengthens DSS’ commitment to advancing its strategic vision by concentrating on key business verticals that drive long-term shareholder value.About DSS, Inc.: DSS, Inc.(NYSE American: DSS) is a multinational company operating businesses across multiple high-growth sectors.

ROCHESTER, N.Y., Feb.26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc.(NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million.

Celios® is a cutting-edge air purification technology featuring a patented three-stage filtration system capable of removing ultrafine particles as small as ten (10) nanometers, helping to improve indoor air quality and mitigate airborne health risks.